Last reviewed · How we verify
NCT04232332
The Phase I Study of Recombinant Human Nerve Growth Factor Injection
Phase 1 trial testing Recombinant human nerve growth factor injection,experimental in Injury of Optic Nerve in 86 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Beijing Tongren Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 86 |
| Start date | 26 December 2019 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 March 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Recombinant human nerve growth factor injection,experimental — full drug profile →
- Recombinant human nerve growth factor injection,single dose — full drug profile →
- Recombinant human nerve growth factor injection,multiple dose — full drug profile →
Conditions studied
- Injury of Optic Nerve — all drugs for Injury of Optic Nerve →
Sponsor
Beijing Tongren Hospital
Who can join
Adults 18 to 45, any sex, with Injury of Optic Nerve. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized, double-blind, placebo-controlled, single/multiple dose study of recombinant human nerve growth factor injection in healthy Chinese volunteers on safety, tolerability and pharmacokinetics
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04232332
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing Tongren Hospital trials
Trials by the same sponsor.
- NCT07499791 — Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis · Phase 2 · not yet recruiting
- NCT07524959 — Antagonism of Neostigmine in Continuous Infusion of Mivacurium · NA · not yet recruiting
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07472764 — Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children · NA · not yet recruiting
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04232332 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tongren Hospital
- Last refreshed: 17 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04232332.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing